In a recent victory, Eisai and Merck have successfully thwarted Shilpa Medicare Ltd. from introducing a generic version of Lenvima for the foreseeable future. This strategic move ensures that the innovative drug will remain unchallenged in the market for at least another decade, securing its position as a leading treatment option. The collaboration between Eisai […]